Non-exclusive agreements for medicinal products containing Nintedanib (ATC L01EX09) under an Open-House model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Nintedanib (ATC-Code: L01EX09) im Wege eines Open-House-Modells
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantity; actual demand is unknown and may be very low.
AOK PLUS may terminate the open house if exclusive agreements are signed; past experience suggests 8-12 months after pu...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Supply of medicinal products containing the active substance Nintedanib (ATC code L01EX09)
- Non-exclusive framework agreement with no minimum purchase obligation
Show full summary
This tender (ID 232797-2026) is an Open-House model for non-exclusive agreements on medicinal products containing Nintedanib (ATC L01EX09) with the health insurance fund AOK PLUS. The procedure is open to all qualified pharmaceutical companies, with no guaranteed volume and no exclusive supply. The contract runs until 30 June 2027, with periodic submission deadlines starting 30 April 2026. No estimated value or award criteria are provided; the notice explicitly states that standard procurement rules do not apply.
Risks
No minimum purchase quantity; actual demand is unknown and may be very low.
AOK PLUS may terminate the open house if exclusive agreements are signed; past experience suggests 8-12 months after pu...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered products
- Must have registered office in Germany, EU, or EEA
Eligibility
- Must submit self-declaration on absence of exclusion grounds (§§ 123, 124 GWB)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive agreements for medicinal products containing Nintedanib (ATC L01EX09) under an Open-House model
Open-House model for non-exclusive agreements for the supply of Nintedanib to AOK PLUS, covering the regions of Saxony and Thuringia. No guaranteed minimum volume; delivery depends on demand. Contract end date is 30 June 2027.
Location
Duration
Category
Award Criteria
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Nintedanib (ATC-Code: L01EX09) im Wege eines Open-House-Modells
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 02 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 232797-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No minimum purchase quantity; actual demand is unknown and may be very low.
AOK PLUS may terminate the open house if exclusive agreements are signed; past experience suggests 8-12 months after pu...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications